Guanhao Biotech Co., Ltd. Class A

Guanhao Biotech Co., Ltd. Class A

SSZSE:300238
9.91
CNY
-0.27
(-2.65%)
0.00EPS
231.03P/E
3.28BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Guanhao Biotech Co., Ltd. Class A carries a market capitalization of 3.28B, placing it among publicly traded companies globally. Its enterprise value stands at 3.09B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.28B
Enterprise Value3.09B

Share Statistics

As of September 30, 2026, Guanhao Biotech Co., Ltd. Class A has 274.70M shares outstanding.

Shares Outstanding274.70M

Valuation Ratios

As of September 30, 2026, Guanhao Biotech Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 231.03. The price-to-sales ratio is 9.09, and the price-to-book ratio stands at 4.82.

PE Ratio231.03
PS Ratio9.09
PB Ratio4.82
P/TBV Ratio5.67

Enterprise Valuation

As of September 30, 2026, Guanhao Biotech Co., Ltd. Class A trades at an EV/EBITDA multiple of 231.35 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 8.97 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 231.35 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 3.09B versus a market cap of 3.28B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales8.97
EV / EBITDA231.35
EV / EBIT231.35

Financial Position

As of September 30, 2026, Guanhao Biotech Co., Ltd. Class A maintains a current ratio of 2.94, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 21.02, indicating elevated leverage, while an interest coverage ratio of 3.49 demonstrates adequate ability to service its debt obligations.

Current Ratio2.94
Quick Ratio1.72
Debt / Equity21.02
Debt / EBITDA9.27
Interest Coverage3.49

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 644,583.10 in revenue per employee across its workforce of 535.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee644,583.10
Employee Count535.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Guanhao Biotech Co., Ltd. Class A recorded 9.15M in income tax expense. That works out to an effective tax rate of 89.01, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 10.28M, leaving 13.57M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax9.15M
Effective Tax Rate89.01

Stock Price Statistics

CNY

As of the close on November 17, 2026, Guanhao Biotech Co., Ltd. Class A's stock has declined approximately 39.83% over the past 52 weeks. The 50-day moving average sits at 11.07, while the 200-day moving average is 12.89.

52-Week Price Change-39.83%
50-Day Moving Average11.07
200-Day Moving Average12.89

Income Statement

CNY

Over the twelve months ended September 30, 2026, Guanhao Biotech Co., Ltd. Class A generated 344.85M in revenue and converted that into 13.57M in net income, yielding earnings per share of 0.00. EBITDA reached 13.37M, while operating income came in at 16.27M.

Revenue344.85M
Gross Profit259.97M
Operating Income16.27M
Pretax Income10.28M
Net Income13.57M
EBITDA13.37M
EBIT13.37M

Balance Sheet

CNY

As of September 30, 2026, Guanhao Biotech Co., Ltd. Class A holds 222.53M in cash and equivalents against 123.94M in total debt, resulting in a net debt position of -103.89M. Total book value stands at 680.94M, with working capital of 250.50M providing operational flexibility.

Cash & Cash Equivalents222.53M
Total Debt123.94M
Net Debt-103.89M
Equity (Book Value)680.94M
Book Value Per Share2.48
Working Capital250.50M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-29.79M

Margins

Over the twelve months ended September 30, 2026, Guanhao Biotech Co., Ltd. Class A posted a gross margin of 75.38, reflecting its pricing power and cost economics. The operating margin of 4.72 and net profit margin of 3.94 provide insight into operational efficiency.

Gross Margin75.38
Operating Margin4.72
Pretax Margin2.98
Profit Margin3.94
EBITDA Margin3.88

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Guanhao Biotech Co., Ltd. Class A paid dividends of 0.01 per share. The dividend payout ratio of -32.42 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -2.93, meaning Guanhao Biotech Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dividend Per Share0.01
Payout Ratio-32.42
Shareholder Yield-2.93

Stock Splits

Guanhao Biotech Co., Ltd. Class A's most recent stock split took place on April 16, 2015 with a 1:2 split ratio.

Last Split Date4/16/2015
Split Ratio1:2

Scores

As of September 30, 2026, Guanhao Biotech Co., Ltd. Class A has an Altman Z-Score of 7.76, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score7.76